Eisai expands India presence
Eisai, a pharma major from Japan, has given a thrust to their India
operations by setting up a manufacturing and process research base in
India. The company has made a total investment of nearly Rs 232 crore
($50 million) on this 50-acre campus located at the Special Economic
Zone (SEZ) at Jawaharlal Nehru Pharma City in Visakhapatnam, Andhra
Unlike its Japanese counterparts, Eisai, a pharma major from Japan has
set-up a facility in India rather than acquiring an Indian market
leader. By setting up a manufacturing and process research base in the
country, Eisai, has given a thrust to its India operations. The
facility known as the Eisai Knowledge Center, is located at the SEZ at
Jawaharlal Nehru Pharma City in Visakhapatnam, Andhra Pradesh.
The company has made a total investment of about Rs 232 crore ($50
million) on this 50-acre campus. The facility, which is scheduled to
start full-scale operations by September 2010, will be Eisai's first
base to integrate active pharmaceutical ingredients (APIs), formulation
manufacturing and API process research on one site.
According to Sanjit Singh Lamba, president, Eisai Pharmatechnology and
Manufacturing, India, this facility would emerge as the global hub for
R&D, formulations and API manufacturing. The center is
aimed at stimulating the knowledge creation between the researchers and
the production team.
Future global hub
The Eisai Knowledge Center was built to create a future global hub
capable of ensuring a stable supply of high quality pharmaceutical
products and achieving innovation in API synthesis processes. With this
facility, the company’s API production will be integrated
with the Kashima plant, Eisai’s another manufacturing plant
The facility in Visakhapatnam employs over 100 people, including 20
research scientists. The company is planning to double it's manpower in
a year's time. The formulation facility has a capacity to produce two
billion tablets annually and the API section has an annual, capacity of
This facility is the fourth knowledge-based center of Eisai worldwide.
The other centers are located at Japan, UK and the US. This is the only
API facility of Eisai outside Japan, which is meant for global
pharmaceutical market. The company is expecting approval for this setup
from various regulatory bodies by the end of 2010.
“Initially, we would use the facility to manufacture two of
our blockbuster products — Aricept and Myonal. We are also
exploring the option of shifting four other products from the facility
in Japan to the Indian facility,” says Deepak Naik, managing
director, Eisai Pharmaceuticals, Mumbai.
The Alzheimer's drug, Aricept, contributes nearly Rs 14,800 crore ($3.2
billion) to the total revenue of the company, globally. The drug will
go off patent in 2012. According to Naik, the company would work on
additional indications for Aricept to add value on it in order to take
on competition from generic players.
The company has plans to expand the existing facility to accommodate
newer products and it will also build a new 50-acre facility by next
quarter, but the location is yet to be decided.
Brings global standards to India
Headquartered in Tokyo, Eisai is a research-based human healthcare
company that discovers, develops and markets pharmaceutical products
throughout the world. Eisai focuses on three therapeutic areas:
integrative neuroscience, oncology, and vascular/ immunological
reaction. The company has production facilities in Japan, the UK, the
US, China, Taiwan and Indonesia. Its R&D facilities are in
Japan,the UK and the US, with over 10,000 employees worldwide.
Eisai has a marketing presence in India since 2004 through its
wholly-owned subsidiary, Eisai Pharmaceuticals in Mumbai. The company's
pipeline is affluent with eight to 10 new chemical entities in
different stages of development. The company also has six monoclonal
antibodies in the pipeline, which is in phase II of development. The
Eisai team in India will now become a part of the global development
process, thereby, bringing Japanese quality standards to India.
The company, which spends 19 percent of its revenues on research and
development, would export 51 percent of its production from this
facility located at Visakhapatnam to other countries.
Eisai is shifting its focus to oncology and critical care, where there
are several unmet medical needs. The last three major acquisition the
company executed, throws light on this. In October 2006, it acquired
four anti-cancer products from the US-based Ligand Pharmaceuticals,
while in April 2007, it acquired US-based bioventure, Morphotek,that
has proprietary human antibody technologies. The acquisition of another
US firm, MGI Pharma, in January 2008 added key products such as Aloxi,
an anti-emetic agent and Dacogen, a DNA hypomethylating agent to the
Ajeesh Anand in